Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C ( CHC CHC ) infected patients evaluated with controlled attenuation parameter ( CAP CAP )

摘要

Summary A novel controlled attenuation parameter ( CAP ) using FibroScan ? has been developed for assessment of liver steatosis. The aim was to evaluate the frequency and associated factors for moderate/severe steatosis evaluated by CAP in CHC patients submitted to transient elastography ( TE ) by FibroScan ? . CHC patients underwent TE with CAP evaluation. The classification of steatosis was defined as: CAP 222 dB /m? = ?S0; CAP ≥ 222 dB /m and 233dB/m? = ?S1; ≥233 dB /m??290dB/m? = ?S2 and = 290 dB /m? = ?S3. The prevalence of moderate/severe steatosis ( CAP ≥ S2) and the related independent factors were identified by a logistic regression analysis. A significance level of 5% was adopted. 1104 CHC patients, 85% genotype‐1 were included (mean age 55?±?11?years; 46% male, mean BMI 25?±?4 Kg/m 2 ). Systemic arterial hypertension and type 2 diabetes mellitus prevalences were 39% and 17%, respectively. Liver stiffness measurement ≥ 9.5 kP a was observed in 39% of patients and steatosis was identified in 50% (S1?=?7%, S2?=?28% and S3?=?15%). The variables independently associated with moderate/severe steatosis were: male gender ( OR =1.35; P? = ? .037; 95% CI :1.01‐1.81); systemic arterial hypertension ( OR =1.57; P? = ? .002; 95% CI :1.17‐2.10) and BMI ( OR =1.17; P? ? .01;95% CI :1.12‐1.22). In conclusion, when CAP was adopted as a tool to detect steatosis, genotype 1 CHC patients presented a high prevalence of moderate/advanced steatosis. In these patients, liver steatosis was associated mostly to metabolic factors (arterial hypertension and high BMI).